Needham & Company LLC Reaffirms “Buy” Rating for NextCure (NASDAQ:NXTC)

Needham & Company LLC reiterated their buy rating on shares of NextCure (NASDAQ:NXTC) in a research note published on Friday morning, Benzinga reports. Needham & Company LLC currently has a $4.00 price objective on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $8.00 price target on shares of NextCure in a report on Friday, May 31st.

NextCure Price Performance

Shares of NASDAQ NXTC traded down $0.02 during trading on Friday, hitting $1.58. The stock had a trading volume of 58,311 shares, compared to its average volume of 164,401. The firm has a fifty day moving average of $1.55 and a two-hundred day moving average of $1.57. The company has a market capitalization of $44.20 million, a PE ratio of -0.70 and a beta of 0.68. NextCure has a 12 month low of $0.98 and a 12 month high of $2.57.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.19). On average, equities analysts expect that NextCure will post -1.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NextCure

Hedge funds have recently modified their holdings of the stock. Marquette Asset Management LLC purchased a new stake in NextCure in the fourth quarter worth $66,000. Acuitas Investments LLC grew its stake in shares of NextCure by 30.0% during the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock worth $425,000 after acquiring an additional 85,982 shares during the period. Assenagon Asset Management S.A. purchased a new stake in NextCure in the 1st quarter worth about $952,000. Cable Car Capital LLC bought a new stake in NextCure in the 4th quarter valued at about $702,000. Finally, Vanguard Group Inc. lifted its holdings in NextCure by 9.3% during the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after purchasing an additional 83,700 shares during the last quarter. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.